Catalyst Wire Dossier Catalyst Wire Dossier

Axalimogene filolisbac

Axalimogene filolisbac · Advaxis, Inc.
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Axalimogene filolisbac, covering 2023-03-20 to 2024-05-20. Get the full timeline:

Most recent: Clinical Trial Update: Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer [Phase 1]

See pricing